CompuGroup Medical (CMPUY.PK) announced that its net income attributable to shareholders of the parent company for the second quarter fell to 13.9 million euros, down from 31.5 million euros in the same period last year. Consequently, earnings per share decreased to 0.27 euros from 0.60 euros, while adjusted earnings per share slipped to 0.34 euros from 0.62 euros.
For the second quarter, revenues amounted to 277.23 million euros, compared to 304.18 million euros in the previous year. On an organic basis, revenue experienced a 9% year-on-year decline. When adjusted for one-time effects from the TI hardware connector exchange and software upgrade, the revenue saw a 1% year-on-year decrease.
The company's guidance for the 2024 fiscal year, initially published on February 7, 2024, was revised on July 9. The new projections account for organic revenue development and adjusted EBITDA. The adjusted EBITDA is now expected to be between 220 million euros and 250 million euros, down from the previous range of 270 million euros to 310 million euros. The organic revenue development forecast has been modified to a range of a 2% decline to 0% growth, revised from the earlier prediction of 4% to 6% growth.
